Cargando…
Zirconium-Porphyrin PCN-222: pH-responsive Controlled Anticancer Drug Oridonin
Drug delivery carriers with a high drug loading capacity and biocompatibility, especially for controlled drug release, are urgently needed due to the side effects and frequent dose in the traditional therapeutic method. Guided by nanomaterials, we have successfully synthesized zirconium-based metal−...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304552/ https://www.ncbi.nlm.nih.gov/pubmed/30622595 http://dx.doi.org/10.1155/2018/3249023 |
_version_ | 1783382386516426752 |
---|---|
author | Leng, Xin Huang, Hongliang Wang, Wenping Sai, Na You, Longtai Yin, Xingbin Ni, Jian |
author_facet | Leng, Xin Huang, Hongliang Wang, Wenping Sai, Na You, Longtai Yin, Xingbin Ni, Jian |
author_sort | Leng, Xin |
collection | PubMed |
description | Drug delivery carriers with a high drug loading capacity and biocompatibility, especially for controlled drug release, are urgently needed due to the side effects and frequent dose in the traditional therapeutic method. Guided by nanomaterials, we have successfully synthesized zirconium-based metal−organic frameworks, Zr-TCPP (TCPP: tetrakis (4-carboxyphenyl) porphyrin), namely, PCN-222, which is synthesized by solvothermal method. And it has been designed as a drug delivery system (DDS) with a high drug loading of 38.77 wt%. In our work, PCN-222 has achieved pH-sensitive drug release and showed comprehensive SEM, TEM, PXRD, DSC, FTIR, and N(2) adsorption-desorption. The low cytotoxicity and good biocompatibility of PCN-222 were certificated by the in vitro results from an MTT assay, DAPI staining, and Annexin V/PI double-staining even cultivated L02 cells and HepG2 cells for 48h. Furthermore, Oridonin, a commonly used cancer chemotherapy drug, is adsorbed into PCN-222 via the solvent diffusion technique. Based on an analysis of the Oridonin release profile, results suggest that it can last for more than 7 days in vitro. And cumulative release rate of Ori at the 7 d was about 86.29% and 63.23% in PBS (pH 5.5 and pH 7.2, respectively) at 37°C. HepG2 cells were chosen to research the cytotoxicity of PCN-222@Ori and free Oridonin. The results demonstrated that the PCN-222@Ori nanocarrier shows higher cytotoxicity in HepG2 cells compared to Oridonin. |
format | Online Article Text |
id | pubmed-6304552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-63045522019-01-08 Zirconium-Porphyrin PCN-222: pH-responsive Controlled Anticancer Drug Oridonin Leng, Xin Huang, Hongliang Wang, Wenping Sai, Na You, Longtai Yin, Xingbin Ni, Jian Evid Based Complement Alternat Med Research Article Drug delivery carriers with a high drug loading capacity and biocompatibility, especially for controlled drug release, are urgently needed due to the side effects and frequent dose in the traditional therapeutic method. Guided by nanomaterials, we have successfully synthesized zirconium-based metal−organic frameworks, Zr-TCPP (TCPP: tetrakis (4-carboxyphenyl) porphyrin), namely, PCN-222, which is synthesized by solvothermal method. And it has been designed as a drug delivery system (DDS) with a high drug loading of 38.77 wt%. In our work, PCN-222 has achieved pH-sensitive drug release and showed comprehensive SEM, TEM, PXRD, DSC, FTIR, and N(2) adsorption-desorption. The low cytotoxicity and good biocompatibility of PCN-222 were certificated by the in vitro results from an MTT assay, DAPI staining, and Annexin V/PI double-staining even cultivated L02 cells and HepG2 cells for 48h. Furthermore, Oridonin, a commonly used cancer chemotherapy drug, is adsorbed into PCN-222 via the solvent diffusion technique. Based on an analysis of the Oridonin release profile, results suggest that it can last for more than 7 days in vitro. And cumulative release rate of Ori at the 7 d was about 86.29% and 63.23% in PBS (pH 5.5 and pH 7.2, respectively) at 37°C. HepG2 cells were chosen to research the cytotoxicity of PCN-222@Ori and free Oridonin. The results demonstrated that the PCN-222@Ori nanocarrier shows higher cytotoxicity in HepG2 cells compared to Oridonin. Hindawi 2018-12-04 /pmc/articles/PMC6304552/ /pubmed/30622595 http://dx.doi.org/10.1155/2018/3249023 Text en Copyright © 2018 Xin Leng et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Leng, Xin Huang, Hongliang Wang, Wenping Sai, Na You, Longtai Yin, Xingbin Ni, Jian Zirconium-Porphyrin PCN-222: pH-responsive Controlled Anticancer Drug Oridonin |
title | Zirconium-Porphyrin PCN-222: pH-responsive Controlled Anticancer Drug Oridonin |
title_full | Zirconium-Porphyrin PCN-222: pH-responsive Controlled Anticancer Drug Oridonin |
title_fullStr | Zirconium-Porphyrin PCN-222: pH-responsive Controlled Anticancer Drug Oridonin |
title_full_unstemmed | Zirconium-Porphyrin PCN-222: pH-responsive Controlled Anticancer Drug Oridonin |
title_short | Zirconium-Porphyrin PCN-222: pH-responsive Controlled Anticancer Drug Oridonin |
title_sort | zirconium-porphyrin pcn-222: ph-responsive controlled anticancer drug oridonin |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304552/ https://www.ncbi.nlm.nih.gov/pubmed/30622595 http://dx.doi.org/10.1155/2018/3249023 |
work_keys_str_mv | AT lengxin zirconiumporphyrinpcn222phresponsivecontrolledanticancerdrugoridonin AT huanghongliang zirconiumporphyrinpcn222phresponsivecontrolledanticancerdrugoridonin AT wangwenping zirconiumporphyrinpcn222phresponsivecontrolledanticancerdrugoridonin AT saina zirconiumporphyrinpcn222phresponsivecontrolledanticancerdrugoridonin AT youlongtai zirconiumporphyrinpcn222phresponsivecontrolledanticancerdrugoridonin AT yinxingbin zirconiumporphyrinpcn222phresponsivecontrolledanticancerdrugoridonin AT nijian zirconiumporphyrinpcn222phresponsivecontrolledanticancerdrugoridonin |